Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.395
-0.025 (-0.73%)
Oct 10, 2025, 12:49 PM EDT - Market open
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
715.29M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 257.00K | - | - |
Dec 31, 2019 | - | - | - |
Dec 31, 2018 | - | - | - |
Dec 31, 2017 | - | - | - |
Dec 31, 2016 | 400.00K | 346.00K | 640.74% |
Dec 31, 2015 | 54.00K | - | - |
Dec 31, 2014 | - | - | - |
Dec 31, 2013 | - | - | - |
Dec 31, 2012 | - | - | - |
Dec 31, 2011 | - | - | - |
Dec 31, 2010 | 488.96K | 188.96K | 62.99% |
Dec 31, 2009 | 300.00K | -200.00K | -40.00% |
Dec 31, 2008 | 500.00K | - | - |
Dec 31, 2007 | 500.00K | - | - |
Dec 31, 2006 | - | - | - |
Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SVRA News
- 1 day ago - Savara: Back On Track With Upcoming APAP BLA Filing - Seeking Alpha
- 4 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA - PRNewsWire
- 4 days ago - SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - GlobeNewsWire
- 7 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - PRNewsWire
- 7 days ago - Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 - Business Wire
- 11 days ago - Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 19 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - GlobeNewsWire
- 24 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA - GlobeNewsWire